Heat Biologics, Inc. has received $-0.07 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 91.03%.
Heat Biologics, Inc. reported better than expected with a surprise EPS of 46.67% or $0.07 during its most recent quarterly earnings. The Actual EPS was $-0.08 compared to the Estimated EPS of $-0.15.
In the last quarter, Heat Biologics, Inc. reported Annual Earnings of $-0.08. Based on the filings, last years Annual Earnings was, $-2.53. In the last Quarter, HTBX reported a surprise Earnings per Share of 46.67% . The consensus estimate for current quarter is $-0.07 and for the current fiscal year, the estimate is $-0.66. For the Next fiscal year, the estimate is $-0.76 based on the consensus.
Heat Biologics, Inc. (NASDAQ:HTBX) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.0595 points or 5.95% at $0.9405 with 1,342,713 shares getting traded. Post opening the session at $0.97, the shares hit an intraday low of $0.9303 and an intraday high of $1.03 and the price was in this range throughout the day. The company has a market cap of $22 million and the number of outstanding shares has been calculated to be 23,883,373 shares. The 52-week high of Heat Biologics, Inc. (NASDAQ:HTBX) is $3.35 and the 52-week low is $0.401.
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Companys products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina.